Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

34.31 +0.57 (+1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
From Veracyte, Inc.
Via Business Wire
Expert Ratings For Veracyte
Within the last quarter, Veracyte (NASDAQ:VCYT) has observ... 
Via Benzinga
Expert Ratings for Veracyte
Analysts have provided the following ratings for Veracyte (NASDAQ:VCYT) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 0... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
From Veracyte, Inc.
Via Business Wire
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
From Veracyte, Inc.
Via Business Wire
Looking Into Veracyte's Return On Capital Employed
During Q1, Veracyte's (NASDAQ:VCYT) reported sales totaled $36.70 million. Despite a 462.62% in earnings, the company posted a loss of $45.41 million. Veracyte collected $34.54... 
Via Benzinga
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Veracyte: Return On Capital Employed Insights
In Q1, Veracyte (NASDAQ:VCYT) posted sales of $36.70 million. Earnings were up 462.62%, but Veracyte still reported an overall loss of $45.41 million. Veracyte collected $34.54... 
Via Benzinga
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
From Veracyte, Inc.
Via Business Wire
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition
Veracyte Inc (NASDAQ: VCYT) has agreed to acquire HalioDx in a €260 million transaction to accelerate growth and strengthen its position in cancer diagnostics... 
Via Benzinga
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
From Veracyte, Inc.
Via Business Wire
Veracyte to Present at Upcoming Investor Conferences
From Veracyte
Via Business Wire
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
From Veracyte, Inc.
Via Business Wire
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
From Veracyte
Via Business Wire
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
From Veracyte, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Celyad Oncology (NASDAQ:CYAD) sto... 
Via Benzinga
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
Veracyte, Inc. Announces CEO Succession Plan
From Veracyte, Inc.
Via Business Wire
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
Veracyte Announces First Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.